Vascular therapy;Terapia naczyniowa

Polski Przeglad Kardiologiczny

Volumn 7, Issue 4, 2005, Pages 351-358

  Rusiecka, Ewa ^a   Drozdz, Jarosław ^a  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

Author keywords

Angiogenesis; Angiogenic therapy; Arteriogenesis; Vascular therapy; Vasculogenesis

Indexed keywords

ADENOVIRUS VECTOR; CYTOKINE; FIBROBLAST GROWTH FACTOR 2; FIBROBLAST GROWTH FACTOR 4; VASCULOTROPIN;

ADOPTIVE IMMUNOTHERAPY; ANGIOGENESIS; BONE MARROW CELL; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CORONARY ARTERY BYPASS GRAFT; ENDOTHELIUM CELL; GENE THERAPY; GENE TRANSFER; HEART MUSCLE REVASCULARIZATION; HUMAN; ISCHEMIC HEART DISEASE; MONONUCLEAR CELL; MORTALITY; PERCUTANEOUS CORONARY INTERVENTION; REVIEW; STEM CELL;

EID: 27544452372     PISSN: 15075540     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (39)

1. Newman M., Kirchner J., Phillips-Bute B. i wsp.: Longitudinal assessment of neurocognitive function after coronary artery bypass surgery. N. Engl. J. Med., 2001, 344, 395-402.
2. Jain R., Munn L.: Leaky vessels? Call Ang1! Nat. Med., 2000, 6, 131-132.
3. Asahara T., Masuda H., Takahashi T. i wsp.: Bone marrow origin of endothelial progenitor cells responsible for postnatal vasculogenesis in physiological and pathological neovascularization. Circ. Res., 1999, 85, 221-228.
4. Kutryk M., Duncan J.: Angiogenesis of the heart. Microsc. Res. Tech., 2003, 60, 138-158.
5. Poltorak Z., Cohen T., Neufeld G.: The VEGF splice variants: properties, receptors and usage for the treatment of ischemic diseases. Herz, 2000, 25, 126-129.
6. Ferrara N., Gerber H., LeCouter J. i wsp.: The biology of VEGF and its receptors. Nat. Med., 2003, 9, 669-676.
7. Vacca A., Ribatti D., Iurlaro M. i wsp.: Human lymphoblastoid cells produce extracellular matrix-degrading enzymes and induce endothelial cell proliferation, migration, morphogenesis, and angiogenesis. Int. J. Clin. Lab. Res., 1998, 28, 55-68.
8. Carmeliet P.: Biomedicine. Clotting factors build blood vessels. Science, 2001, 293, 1602-1604.
9. Jackson C.: Matrix metalloproteinases and angiogenesis. Curr. Opin. Nephrol. Hypertens., 2002, 11, 295-299.
10. Takagi H., Koyama S., Seike H. i wsp.: Potential role of the angiopoietin/tie2 system in ischemia-induced retinal neovascularization. Invest. Ophthalmol. Mol. Vis. Sci., 2003, 44, 393-402.
11. Shim W., Bapna A., Teh M. i wsp.: Angiopoietin-1 promotes tumor angiogenesis and tumor vessel plasticity of human cervical cancer in mice. Exp. Cell. Res., 2002, 279, 299-309.
12. Visconti R., Richardson C., Sato T.: Orchestration of angiogenesis and arteriovenous contribution by angiopietins and VEGF. Proc. Natl. Acad. Sci. USA, 2002, 99, 8219-8224.
13. Maisonpierre P., Suri C., Jones P. i wsp.: Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis. Science, 1997, 277, 55-60.
14. Bergers G., Benjamin L.: Tumorigenesis and the angiogenic switch. Nat. Rev., 2003, 3, 401-410.
15. Dor Y., Djonov V., Abramovitch R. i wsp.: Conditional switching of VEGF provides new insights into adult neovascularization and proangiogenic therapy. EMBO J., 2002, 21, 1939-1947.
16. Benjamin L., Golijanin D., Itin A. i wsp.: Selective ablation of immature blood vessels in established human tumors follows VEGF withdrawal. J. Clin. Invest., 1999, 103, 159-165.
17. Luttun A., Tjwa M., Carmeliet P.: Placental growth factor (PIGF) and its receptor Flt-1 (VEGFR-1): novel therapeutic targets for angiogenic disorders. Ann. N Y Acad. Sci., 2002, 979, 80-93.
18. Ye C., Feng C., Wang S. i wsp.: sFlt-1 gene therapy of follicular thyroid carcinoma. Endocrinology, 2004, 145, 817-822.
19. Maseri A., Araujo L., Finocchiaro M.: Collateral development and function in man. [w:] Schaper W., Schaper J.(red.): Collateral Circulation: Heart, Brain, Kidney, Limbs. MA: Kluwer Academic Publisher, Boston 1993, 381-402.
20. Helisch A., Schaper W.: Arteriogenesis, The Development and growth of collateral Arteries. Microcirculation, 2003, 10, 83-97.
21. Schaper J., Konig R., Franz D. i wsp.: The endothelial surface of growing coronary collateral arteries: Intimal margination and diapedesis of monocytes. Virchows Arch., 1976, 370, 193-205.
22. Schaper J., Borgers M., Xhonneux R. i wsp.: Cortisone influences developing collaterals: A morphologic study. Virchows Arch., 1973, 361, 263-282.
23. Galis Z., Khatri J.: Matrix metalloproteinases in vascular remodeling and atherogenesis: The good, the bad, and the ugly. Circ. Res., 2002, 90, 251-262.
24. Buschmann I., Hoefer I., van Royen N. i wsp.: GM-CSF: a strong arteriogenic factor acting by amplification of monocyte function. Atherosclerosis, 2001, 59, 343-356.
25. Resnick N., Collins T., Atkinson W. i wsp.: Platelet-derived growth factor B chain promotor contains a cis-acting fluid shear-stress-responsive element. Proc. Natl. Acad. Sci. USA, 1993, 90, 4591-4595.
26. Nishida K., Harrison D., Navas J. i wsp.: Molecular cloning and characterization of the constitutive bovine aortic endothelial cell nitric oxide synthase. J. Clin. Invest., 1992, 90, 2092-2096.
27. Tronc F., Mallat Z., Lehoux S. i wsp.: Role of matrix metalloproteinases in blond flow-induced arteria enlargement interaction with NO. Arterioscler. Thromb. Vasc. Biol., 2000, 20, E120-E126.
28. Schaper W., Scholz D.: Factor regulating arteriogenesis. Arterioscler. Thromb. Vasc. Biol., 2003, 23, 1143-1151.
29. Busiek D., Baragi V., Nehring L. i wsp.: Matrilysin expression by human mononuclear phagocytes and its regulation by cytokines and hormones. J. Immunol., 1995, 154, 6484-6491.
30. Isner J., Baumgartner I., Rauh G. i wsp.: Treatment of thromboangititis obliterans (Buerger's disease) by intramuscular gene transfer of vascular endothelial growth factor: preliminary clinical results. J. Vasc. Surg., 1998, 28, 964-973.
31. Simons M., Annex B., Laham R. i wsp.: Pharmacological treatment of coronary artery disease with recombinant fibroblast growth factor-2: double-blind, randomized, controlled clinical trial. Circulation, 2002, 105, 788-793.
32. Henry T., Abraham J.: Review of preclinical and clinical results with vascular endothelial growth factors for therapeutic angiogenesis. Curr. Intervent. Cardiol. Rep., 2000, 2, 228-241.
33. Grines C., Watkins M., Helmer G. i wsp.: Angiogenic Gene Therapy (AGENT) trial in patients with stable angina pectoris. Circulation, 2002, 105, 1291-1297.
34. Douglas W., Losordo M.: Therapeutic Angiogenesis and Vasculogenesis for Ischemic Disease Part II: Cell-Based Therapies. Circulation, 2004, 109, 2692-2697.
35. de Bont E., Guikema J., Scherpen F. i wsp.: Mobilized human CD34+ hematopoietic stem cells enhance tumor growth in a nonobese diabetic/severe combined immunodeficient mouse model of human non-Hodgkin's lymphoma. Cancer Res., 2001, 61, 7654-7659.
36. Perin E., Dohmann H., Borojevic R. i wsp.: Transendocardial, autologous bone marrow cell transplantation for severe, chronic ischemic heart failure. Circulation, 2003, 107, 2294-2302.
37. Tse H., Kwong Y., Chan J. i wsp.: Angiogenesis in ischaemic myocar-dium by intramyocardial autologous bone marrow mononuclear cell implantation. Lancet, 2003, 361, 47-49.
38. Fuchs S., Satler L., Kornowski R. i wsp.: Catheter-based autologous bone marrow myocardial injection in no-option patients with advanced coronary artery disease: a feasibility study. J. Am. Coll. Cardiol., 2003, 41, 1721-1724.
39. Folkman J.: Tumor angiogenesis: therapeutic implications. N. Engl. J. Med., 1971, 285, 1182-1186.